Cyclophosphamide oral - Hikma Pharmaceuticals

Drug Profile

Cyclophosphamide oral - Hikma Pharmaceuticals

Latest Information Update: 13 Apr 2016

Price : $50

At a glance

  • Originator Roxane Laboratories
  • Developer Hikma Pharmaceuticals
  • Class Antineoplastics; Antirheumatics; Cyclophosphamides; Myeloablative agonists; Small molecules
  • Mechanism of Action Alkylating agents; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia; Breast cancer; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Hodgkin's disease; Multiple myeloma; Mycosis fungoides; Myeloid leukaemia; Neuroblastoma; Non-Hodgkin's lymphoma; Ovarian cancer; Retinoblastoma

Most Recent Events

  • 07 Jun 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top